Aiko Ito

Title: Aiko Ito: Innovator in Cancer Treatment

Introduction

Aiko Ito is a prominent inventor based in Kagawa, Japan. She has made significant contributions to the field of cancer treatment through her innovative research and development of modified galectin 9 proteins. With a total of 2 patents to her name, Aiko is recognized for her groundbreaking work in immunology and oncology.

Latest Patents

Aiko Ito's latest patents include "Modified galectin 9 proteins and methods of treatment using them" and "Modified galectin 9 proteins and use thereof." These patents describe a recombinant galectin 9 (rGal 9) that exhibits immune system-mediated actions and direct effects on tumor cells. The rGal 9 is potent in inducing the inhibition of cancer metastasis and reduction. Importantly, it exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, particularly CD4-positive T cells, which can lead to an excessive immune response. Additionally, the rGal 9 has a potent apoptosis-inducing property on synovial cells involved in joint deformation in rheumatism. However, the link domain linking two carbohydrate recognition domains (CRDs) in galectin 9 is highly susceptible to protease, making it easily digestible and losing its activities. Therefore, Aiko's research emphasizes the need for a more stabilized molecule to enhance its efficacy without undesirable effects.

Career Highlights

Aiko Ito is currently associated with Galpharma Co., Ltd., where she continues her research and development efforts. Her work has garnered attention in the scientific community, particularly for its potential applications in cancer therapy.

Collaborations

Aiko collaborates with notable colleagues, including Nozomu Nishi and Mitsuomi Hirashima, who contribute to her research endeavors.

Conclusion

Aiko Ito's innovative work in the field of modified galectin 9 proteins represents a significant advancement in cancer treatment. Her contributions are paving the way for new therapeutic strategies that could improve patient outcomes in oncology.